StratDeck

Two stocks in Healthcare

Hikma Pharmaceuticals vs Smith & Nephew: profit, growth, debt and price compared

Hikma Pharmaceuticals is stronger on 5 of 7 figures: profit margin, price for its expected profit, dividend, analysts' view and price trend. Smith & Nephew is stronger on 2: sales growth and debt.

Figures as of 18 November 2026Yahoo Finance
Explore Hikma Pharmaceuticals' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Hikma Pharmaceuticals and Smith & Nephew side by side
Hikma PharmaceuticalsHIK.LSmith & NephewSN.L
Net marginStronger: 11.3%10.1%
Revenue growth, past year+4.20%Stronger: +4.60%
Debt to equity77.1%Stronger: 73.1%
Forward P/EStronger: 9.2×13.2×
Dividend yieldStronger: 3.84%2.55%
AnalystsStronger: Strong buy · 12Hold · 17
From its 200-day averageStronger: +5.8%+1.4%

Share price over the past year

  • Hikma Pharmaceuticals+7.7%
  • Smith & Nephew−6.8%

20 Nov 202518 Nov 2026

Hikma Pharmaceuticals or Smith & Nephew: which is stronger?

  • HIK.L

    Which is more profitable?

    Hikma Pharmaceuticals keeps more of each sale as profit: 11.3% against 10.1%.

  • SN.L

    Which is growing its sales faster?

    Smith & Nephew is growing its sales faster: +4.60% over the past year, against +4.20%.

  • SN.L

    Which has borrowed less?

    Smith & Nephew has borrowed less: its debt is 73.1% of what its shareholders own, against 77.1% for Hikma Pharmaceuticals.

  • HIK.L

    Which costs less for the profit it is expected to make?

    Hikma Pharmaceuticals costs less for the profit it is expected to make: 9.2× its forward earnings, against 13.2×.

  • HIK.L

    Which pays more in dividends?

    Hikma Pharmaceuticals pays more back in dividends for what a share costs: 3.84% a year, against 2.55%.

  • HIK.L

    Which do analysts rate higher?

    Analysts are warmer on Hikma Pharmaceuticals: Strong buy, against Hold for Smith & Nephew.

  • HIK.L

    Which is in the stronger price trend?

    Hikma Pharmaceuticals' price is in the stronger trend: 5.8% above its 200-day average, against 1.4% above.

What each company does

HIK.LHikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.

Reports results on 25 February 2027

SN.LSmith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.

Reports results on 1 March 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every UK healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.